Immunotherapy Combination Extends Mesothelioma Survival

Standard-of-care treatment for unresectable pleural mesothelioma cancer could be changing soon, sparked by a recently completed international study of a novel immunotherapy combination. Patients in the randomized mesothelioma clinical trial who were treated with ipilimumab (Yervoy) and nivolumab (Opdivo) had a median overall survival of 18.1 months, compared to 14.1 months for those receiving chemotherapy. The results of the mesothelioma trial, which was sponsored by Bristol Myers Squibb, were presented at the recent World Conference on Lung Cancer virtual meeting. Authors of the study said it was the first time an immunotherapy combination used in a first-line setting for pleural mesothelioma improved survival in a large phase III clinical trial. “Nivolumab and ipilimumab should be considered as a new standard of care,” said study presenter Dr. Paul Baas of the Netherlands Cancer Institute in Amsterdam. “This is a clear signal that this treatment could be of great use for these patients.” Survival Benefit Greatest in Hard-to-Treat Mesothelioma Subtypes While the survival improvement was modest overall, there was a dramatic improvement in the traditionally toughest-to-treat mesothelioma subtypes. For patients with non-epithelioid histology (sarcomatoid or biphasic), median survival was 18.1 months for those receiving the immunotherapy treatment, and only 8.8 months for those receiving standard chemotherapy. At 24 months, the overall survival rate for...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Abstract Malignant pleural mesothelioma is an aggressive, deadly cancer often requiring input from multiple medical disciplines. Treatment has evolved over the last several decades with increasing evidence and ongoing advances in chemotherapy, radiation, and immunotherapy; however, no standard treatment regimen has yet been defined. Regardless of the overall strategy, surgery remains the foundation of treatment to remove macroscopic disease, and preservation of lung parenchyma via extended pleurectomy/decortication may be preferable to extrapleural pneumonectomy. PMID: 33012435 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Thorac Surg Clin Source Type: research
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Pharmaceutical giant Merck has teamed up with Novocure to test its cornerstone immunotherapy, pembrolizumab (Keytruda), alongside Tumor Treating Fields. The new phase II clinical research trial is focusing on non-small cell lung cancer and will enroll approximately 66 patients across the U.S. Keytruda, Merck’s anti-PD-1 therapy, works as a checkpoint inhibitor and allows the immune system to identify and attack cancer cells hiding within the PD-1 pathway. The FDA approved Keytruda for mesothelioma as the first immunotherapy treatment for the disease in 2020. Novocure, a global oncology company, has been developing...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated. The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers. While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I. Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or without chemotherapy, and/or radiation therapy. The mechanism of carcinogenesis has not been fully elucidated, although approximately 80% of cases can still be linked to asbestos exposure. The tumor immune microenvironment (TME) has been proven to play an important role in MPM pathogenesis and treatment...
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research
Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options. A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusions: Since its introduction, PERCIST 1.0 has been increasingly used in many clinical trials and prospective studies, with variable reporting of metabolic response and survival data. In general, it appears PERCIST response is associated with longer PFS and survival though the heterogeneity of disease, scan timing and therapies make data pooling difficult. Prospective inclusion of the PERCIST 1.0 criteria in clinical trials using FDG, with baseline, early monitoring, and end of therapy scans could inform cancer clinical trials. Support: 5U01CA140204-04 Reference: 1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: NET and Others II Source Type: research
This study is open also to patients with lung cancer or urothelial cancer. In the trial, the use of cabozantinib will be combined with standard-of-care Alimta, the chemotherapy drug generically known as pemetrexed. The study is designed to establish a safe and effective dosage level for both agents when used together. Cabozantinib is known as an inhibitor. It blocks signals that encourage the growth of new blood vessels needed for cancer cells to divide and grow. Blocking those signals can shrink tumors or even cause tumor cell death, leading to significantly longer survival for patients. Cabozantinib will be taken orall...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Three of the country’s leading cancer centers have opened a collaborative clinical trial that potentially could change surgical treatment of mesothelioma. Researchers will measure the safety and efficacy of using two different immunotherapy drug regimens — Opdivo (nivolumab) and Yervoy (ipilimumab) — beginning 42 days before surgery. The hope is that at least one will make surgical resection more effective. Sidney Kimmel Cancer Center at Johns Hopkins University, MD Anderson Cancer Center at the University of Texas and Greenebaum Cancer Center at the University of Maryland are working together to enroll a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Conferences | Environmental Health | France Health | Immunotherapy | Lung Cancer | Mesothelioma | Netherlands Health | Study | Toxicology | USA Health | Yervoy